News

Deal Announcements

Ablexis Accepts $12 Million Venture Capital Funding

Thursday, June 3, 2010 5:29:00 AM PDT | VentureDeal Staff
San Francisco, California  --  Biotechnology company Ablexis has secured $12 million in its first round of venture capital financing.

Ablexis is developing a proprietary transgenic mouse platform to assist in the discovery of human therapeutic antibodies.

Third Rock Ventures led the round, which also included Pfizer Strategic Investments.  The company said it would use the proceeds to continue advancing the development of its platform.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1